A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.
A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.
复制标题
DOI：
10.4274/balkanmedj.2017.0055
复制
发表时间：
2017-01
影响因子：
3
通讯作者：
Demirer T
中科院分区：
文献类型：
--
作者：
Atilla E;Ataca Atilla P;Demirer T
异基因造血干细胞移植（Allo-HSCT）是一种治疗恶性和某些良性血液病的治疗选择。在过去的十年中，许多新的高剂量方案在不同的强度已经开发专门用于血液恶性肿瘤和实体瘤患者。目前，异基因移植前主要有三种方法：清髓性（MA）、低强度预处理（RIC）和非MA（NMA）方案。MA方案导致不可逆的血细胞减少，需要干细胞支持。接受NMA方案的患者具有最小的血细胞减少，并且这种类型的方案可以在没有干细胞支持的情况下给予。RIC方案不符合MA和NMA的标准：血细胞减少是可逆的，需要干细胞支持。NMA/RIC为Allo-HSCT开辟了治疗老年患者和合并症患者的新时代。RIC预处理用于所有Allo-HSCT的40%，并且这种趋势继续增加。在本文中，我们将审查这些方案的设置，特别是异基因造血干细胞移植，我们的目的是描述这些预处理方案的历史，特点和对特定疾病的影响。
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a curative treatment option for both malignant and some benign hematological diseases. During the last decade, many of the newer high-dose regimens in different intensity have been developed specifically for patients with hematologic malignancies and solid tumors. Today there are three main approaches used prior to allogeneic transplantation: Myeloablative (MA), Reduced Intensity Conditioning (RIC) and Non-MA (NMA) regimens. MA regimens cause irreversible cytopenia and there is a requirement for stem cell support. Patients who receive NMA regimen have minimal cytopenia and this type of regimen can be given without stem cell support. RIC regimens do not fit the criteria of MA and NMA: the cytopenia is reversible and the stem cell support is necessary. NMA/RIC for Allo-HSCT has opened a new era for treating elderly patients and those with comorbidities. The RIC conditioning was used for 40% of all Allo-HSCT and this trend continue to increase. In this paper, we will review these regimens in the setting of especially allogeneic HSCT and our aim is to describe the history, features and impact of these conditioning regimens on specific diseases.